

Study of the MFN2^{Ile213Thr} mutant

Supplementary Material 1

1. Electromyography results of the proband.

Muscles	Side	Slack status				Beam fibrillation potential	With mild force				With heavy force				Other	
		Inserted fibrillation potential	fibrillation potential	positive Myotonic potential	Myotonic potential		average time (ms)	average amplitude (mv)	polyphasic potential	giant potential	Myopathy potential	Interference phase	mixed phase	pure phase	largest amplitude	
tibialis anterior	left	10	10	10			↑	↑								√
peroneus longus	left	10	10	10			↑	↑								√
extensor digitorum brevis	left	10	10	20			↑	↑								√
musculus gastrocnemius	left	0					0	0								√
medial vastus muscle	left	0					↑	↑								√
tibialis anterior	right	10	10	20			↑	↑								√
peroneus longus	right	10	10	10			↑	↑								√
extensor digitorum brevis	right	10	10	20			↑	↑								√
musculus gastrocnemius	right	0					0↑	0↑								√
medial vastus muscle	right	10	10	10			↑	↑								√
paravertebral muscle T11	right	-		10			↑	↑								
paravertebral muscle T12	left	0					0	0								
first dorsal interosseus	left	0					↑	↑								√
musculi abductor pollicis brevis	left	0					↑	↑							√	√
extensor digitorum	left	0					↑	↑								√
deltoides triangularis	left	0					0	0								√
bicipital muscle of arm	left	0					0	0								√
first dorsal interosseus	right	-	±	±			↑	↑								√
musculi abductor pollicis brevis	right	0					0↑	0↑								√
extensor digitorum	right	0					0	0								√
deltoides triangularis	right	0					0	0								√
bicipital muscle of arm	right	0					0	0								√

Study of the MFN2^{Ile213Thr} mutant

Nerve	Stimulating spot	Recording spot	Motor nerve conduction				Other	
			Latency time (ms)		Amplitude (mv)			
			left	right	left	right		
deep peroneal nerve	Capitula fibula	tibialis anterior	12.2	20.1	8.4	4.6	11	7
superficial peroneal nerve	Capitula fibula	peroneus longus	14.4	13.8	5.6	7.4	9	11
total peroneal nerve	ankle	extensor digitorum brevis	25.8	7.2	2.8	2.7	7	12
	Capitula fibula		87.0	32.9	2.5	2.7		
nervus tibialis	popliteal fossa	musculus gastrocnemius	16.0	30.3	8.6	3.2	10	7
nervus femoralis		medial vastus muscle	39.4	71.8	2.3	1.0	7	3
ulnar nerve	wrist	first dorsal interosseus	15.1	10.9	7.9	11.4	5	6
	elbow		59.8	53.2	9.0	6.4		Waveform from several
nervus medianus	wrist	musculi abductor pollicis brevis	11.8	12.0	3.8	2.3	4	5
	elbow		58.5	54.6	4.1	1.4		Waveform from several
musculospiralis	radial groove	extensor digitorum	28.9	28.1	2.9	2.3	7	8
musculocutaneous nerve	ERB'S	deltoides triangularis	28.7	20.6	2.0	2.9	9	11
axillary nerve	ERB'S	bicipital muscle of arm	12.1	26.2	6.1	6.7	12	6
Sensory nerve conduction								
Nerve	Stimulating spot	Recording spot	Latency time (ms)		Amplitude (mv)		Excitation rate (m/s)	
			left	right	left	right	left	right
ulnar nerve	little finger	wrist	no SNAP	no SNAP				
nervus medianus	digitus medius	wrist	no SNAP	no SNAP				
superficial peroneal nerve			no SNAP	no SNAP				
nervus suralis			no SNAP	no SNAP				

Results description: Electromyography shows fibrillar, positive phase potential, action potential amplitude, time-limit widening increased when light force; Motor nerve conduction amplitude is normal/mild decrease; nerve conduction velocity is about 10 m/s (which is unusual in CMT2A); sensory nerve conduction is seriously without SNAP.

Study of the MFN2^{Ile213Thr} mutant

2. Detailed data of the vector construction and cell transfection.

(1) cDNA sequences

No. pHS-AVC-LY059 (wild-type) MFN2 (human, NM_014874)

5'-ATGCCCTGCTTCTCGATGCAACTCTATCGCACAGTCAGAAAAATAAGAGACACATGGCTGAGGTG-AATGCATCCCCACTTAAGCACTTGTCACTGCCAAGAAGAAGATCAATGGCATTTTGAGCAGCTGGGGCC-TAC-ATCCAGGAGAGGCCACCTCCTGAAGACACGTACAGGAATGCAGAACTGGACCCGTTACCACAGAAGAACAGTTCTGGACGTCAAAGGTTACCTATCCAAGTGAAGGAGCAGCTGGGATGAGGGCACAGATGCCATGAGGCCTTCTCC-TTACCGAGGGCTCAGAGGAAAGAGGAGTCCAAGACTGTGAACAGCTGGCCATGCCCTCACCAGGACAA-GCAGCTCCATGCCGCAGCCTAGTGAGTGTGATGTGGCCAACCTCTAAGTGCCACTTCTGAAGGATGACCTCG-TTTGATGGACAGCCCTGGTATTGATGTCACCACAGAGCTGGACAGCTGGATTGACAAGTTGTCTGGATGCT-GATGTGTTGTGCTGGCCAACCTCAGAGTCCACCTGATGCAAGCGAAAAGCAGCTTCCACAAGGTGA-GTGAAGCGTCTCCCGGCCAACATCTTCATCCTGAACAACCGCTGGGATGCACTGCCAGAGCCCAGTAC-ATGGAGGAGGTGCCGGCAGCACATGGAGCGTTGATCCAGCTTCTGGGATGAGCTGGCGTGGGATC-GATCCCAGGCCGGGACCGCATCTCTTGCTGCTAAGGAGGTGCTCAACGCCAGGATTGAGAAAGCCA-GGGCATGCCATGAGGAGGGCGCTCGCAGAAGGCTTCAAGTGAGGATGTTGAGTTGAGAATTTGAG-AGGAGATTGAGGAGTGCACTCCCAGTCTGAGCAGACAGCAAGGTTGAGCAGCACAGGTCCGGCCAAGC-AGATTGCAAGGGCGGTTGACTCATGGACTCCCTGCACATGGCGGCTCGGGAGCAGCAGGTTACTGCA-GGAAATGCGTGAAGAGCAGCAAGACCGACTGAAATTATTGACAACAGCTGGAGCTTGGCTCAAGACTA-TAAGCTCGAATTAAGCAGATTACGGAGGAAGTGGAGAGGGCAGGTGTCGACTGCAATGGCCAGGAGATC-AGGCGCCTCTGTACTGGTGGACGATTACAGATGGACTTCCACCCCTCCAGTAGTCTCAAGGTTATAA-GAATGAGCTGCACCGCCACATAGAGGAAGGACTGGGTCGAAACATGTCGACCGCTGCTCACGCCATCAC-CAACTCCCTGCAGACCATGCAGCAGGACATGATAGATGGCTGAAACCCCTTCTGTGCTGTGCGGAG-TCAAGATAGACATGCTGGTCCCACGCCAGTGCTTCCCTCAACTATGACCTAAACTGTGACAAGCTGTGCT-GACTTCCAGGAAGACATTGAGTCCATTCTCTCGGATGGACCATGCTGGTAATAGGTTCTGGGCCCCA-AGAACAGCCGTCGGGCTTGATGGCTACAATGACCAAGGTCCAGCGTCCATCCCTGACGCCAGCCAACCC-CAGCATGCCCACTGCCACAGGGCTCGCTACCCAGGAGGAGTTCATGGTTACCGGCCCTGGG-TCCTTGACATCCAGGACCTCCATGGGCATTCTGTTGGAGGAGTGGTGGGAAGGCAGTGGCTGGGG-CTCATTGCCCTCTCCTTGGGCTTATGGCCTCTACGTCTATGAGCGTCTGACCTGGACCACCAAGGCCAAGGAGAGGGCCTCAAGGCCAGTTGTGAGCAGCGAGAAGCTGCACTGGCTCATCAGCTACACTGG-CTCCAACTGCAAGGCCACCAAGTCAGCAGGAACGTCTGGACCTTGCTCATGTGTCAGCAAGTTGACGTC-ACCCGGGAGAACCTGGAGCAGGAAATTGCCGCACTGAACAAGAAAATTGAGGTTCTGACTCACTCAGAGCA-AAGCAAAGCTCAGGAATAAGCCGGTTGGTGGACAGTGAGCTCAACATGTTCACACACCAGTACCTGCA-GCCCAAGCAGA-3'


No. pHS-AVC-LY060 (mutant) MFN2(human,NM_014874, 638T>C)

5'-ATGCCCTGCTTCTCGATGCAACTCTATCGCACAGTCAGAAAAATAAGAGACACATGGCTGAGGTG-AATGCATCCCCACTTAAGCACTTGTCACTGCCAAGAAGAAGATCAATGGCATTTTGAGCAGCTGGGGCC-TACATCCAGGAGAGGCCACCTCCTGAAGACACGTACAGGAATGCAGAACTGGACCCGTTACCACAGAACAGGTTCTGGACGTCAAAGGTTACCTATCCAAGTGAAGGAGCAGCTGGGATGAGGGCACAGATGCCATGAGGCCTTC-TCCTTACCGAGGGCTCAGAGGAAAGAGGAGTGCCAAGACTGTGAACCAAGCTGGCCATGCCCTCACCAGG-ACAAGCAGCTCCATGCCGGCAGCCTAGTGAGTGTGATGTGGCCAACTCTAAGTGCCACTTCTGAAGGATG-ACCTCGTTGATGGACAGCCCTGGTATTGATGTCACCACAGAGCTGGACAGCTGGACTGACAAGTTGTCT-GGATGCTGATGTGTTGTGCTGGTGGCCAACCTCAGAGTCCACCTGATGCAAGCGAAAAGCAGCTTCTCCA-CAAGGTGAGTGAGCGTCTCCCGGCCAACATCTTCATCCTGAACAACCGCTGGGATGCACTGCCCTCAGA-GCCCGAGTACATGGAGGAGGTGCGGCGGCAGCACATGGAGCGTTGATCAGCTTCTGGGATGAGCTGG-CGTGGTGGATGATCCCAGGCCGGGACCGCATCTTCTTGCTGCTAAGGAGGTGCTCAACGCCAGGATT-CAGAAAGGCCAGGGCATGCCCTGAAGGAGGGGGCGCTCGCAGAAGGCTTCAAGTGAGGATGTTGAGTT-TCAGAATTTGAGAGGAGATTGAGGAGTGCACTCCCAGTCTGCACTGAGTGAAGACCAAGTTGAGCAGCACACG-GTCCGGCCAAGCAGATTGCAAGGGCGTTGACTCATGGACTCCCTGCACATGGCGCTGGGAGCAG-

Study of the MFN2^{Ile213Thr} mutant

CAGGTTACTGCGAGGAAATGCGTAAGAGCGCGAAGACCGACTGAAATTATTGACAAACAGCTGGAGCTCT-TGGCTCAAGACTATAAGCTCGAATTAAGCAGATTACGGAGGAAGTGGAGAGGCAGGTGTCAGTGCAATGG-CCGAGGAGATCAGGCGCCTCTGTACTGGTGGACGATTACAGATGGACTTCCACCCTCTCCAGTAGTCC-TCAAGGTTATAAGAATGAGCTGCACGCCACATAGAGGAAGGACTGGGTCGAAACATGTCTGACCGCTGC-TCCACGCCATACCAACTCCTGCAGACCATGCGAGCAGGACATGATAGATGGCTGAAACCCCTCCTCCT-GTGTCTGTGCGGAGTCAGATAGACATGCTGGTCCCAGGCCAGTGCTCTCCCTCAACTATGACCTAAACTGT-GACAAGCTGTGCTGACTTCCAGGAAGACATTGAGTTCATTCTCTCGGATGGACCATGCTGGTGAATA-GGTTCTGGCCCCAAGAACAGCCGTGGCCTTGATGGCTACAATGACCAGGTCAGCGTCCATCCCTC-TGACGCCAGCCAACCCCCAGCATGCCACAGGGCTCGCTACCCAGGAGGAGTTCATGGTTCC-ATGGTTACCGGCCTGGCCTCTGACATCCAGGACCTCCATGGCATTCTTGTGTTGGAGGAGTGGTGTGG-AAGGCACTGGCTGGCCTCATGCCCTCTCCTTGGCTATGCCCTCTACGTCTATGAGCGTCTGAC-CCTGGACCACCAAGGCCAAGGGAGAGGGCCTCAAGGCCAGTTGTGGAGCATGCCAGCGAGAACGCTGCAG-CTTGTCACTCAGCTACACTGGCTCAACTGCCACCAAGTCCAGCAGGAACCTGTCTGGACCTTGTCTCATC-TGTGTCAGCAAGTTGACGTCACTCAGAGCAAAGCTGCTCAGGAATAAGCCGTTGGTGGACAGTGAGCTAACATGTTCACACACCAAGTACCTGCAGCCCAGCAGA-3'

(2) Vector backbone diagram



(3) Primers used in the vector construction and QF-PCR

Target	Forward-primer	Reverse-primer	Segment length (bp)
MFN2	GGACCCCGTTACCACAGAAAG	TTGTCCCAGAGCATGGCATT	162
MFN2 (638T>C)	GGACCCCGTTACCACAGAAAG	TTGTCCCAGAGCATGGCATT	162
GAPDH	TGACTTCAACAGCGACACCCA	CACCCCTGTTGCTGTAGCCAA	121

(4) Data of QF-PCR (48 h after transfection)

Gene	Group	Repetition 1	Repetition 2	Repetition 3	Mean	SD	QC ¹
MFN2	293FT	0.3	0.3	0.3	0.315	0.014	0.046
	293FT-pHS-AVC-LY059	2452.4	2435.5	2385.4	2424.436	34.872	0.014
	293FT-pHS-AVC-LY060	5673.4	5673.4	5442.3	5596.371	133.432	0.024
	293FT-pHS-BVC-LW345	1.0	1.0	1.0	1.000	0.012	0.012

¹QC, the value of standard deviation/mean. The larger the value, the higher the volatility of the experimental data.

Study of the MFN2^{Ile213Thr} mutant

Supplementary Table 1. List of differentiated compounds

m/z	FC (pHS-AVC- LY059/ pHS-AVC- LY060)	log2(FC)	raw. pval	vip	compound_id	compound_name	adduct	delta (ppm)	sub- class	Source	KEGG_ com- pound	KEGG_ pathway	KEGG_pathway_descrip- tionn
89.9414	3.5093	1.8112	0.079369	1.7718	HMDB0013667	Yttrium	[M+H]+	315	-	Endog- enous	-	-	-
116.9269	3.9056	1.9656	0.045241	1.9133	HMDB0029596	Chloroform	[M-H]-	169	Halo- meth- anes	Endog- enous Food Environ- mental Biological	C13827	-	-
122.0958	0.46894	-1.0925	0.072381	1.798	HMDB0001020	N, N-Dimethyl- aniline	[M+H]+	5	Amines	Endog- enous Food Biological	C02846	-	-
128.0368	4.5875	2.1977	0.004952	2.1955	HMDB0000267	L-5-Oxoproline	[M-H]-	12	Amino acids, peptides, and ana- logues	Endog- enous Food Biological	C01879	map00480; Glutathione metabolism; Metabolic pathways map01100	
137.0271	0.46029	-1.1194	0.055543	1.8665	HMDB0000500	4-Hydroxyben- zoic acid	[M-H]-	20	Benzoic acids and deriva- tives	Endog- enous Food Biological	C00156	map00130; Ubiquinone and other terpenoid-quinone bio- map00362; synthesis; Benzoate degradation; Bisphenol map00363; degradation; Toluene degradation; Amino- map00623; benzoate degradation; Folate biosynthesis; map00627; Biosynthesis of phenylpropanoids; Metabolic map00790; pathways; Biosynthesis of secondary metabo- map01061; lites; Microbial metabolism in diverse environ- map01100; ments; Degradation of aromatic compounds; map01110; Biosynthesis of cofactors; Benzoic acid family map01120; map01220; map01240; map07110	
141.112	0.33401	-1.582	0.003465	2.2178	HMDB0029598	Metenamine	[M+H]+	11	1,3,5-tri- azinanes	Endog- enous Food	-	-	-
167.0225	0.46796	-1.0955	0.054323	1.8719	HMDB0000289	Uric acid	[M-H]-	9	Purines and purine deriva- tives	Endog- enous Food Biological	C00366	map00230; Purine metabolism; Metabolic pathways; Mi- map01100; crobial metabolism in diverse environments; map01120; Bile secretion map04976	

Study of the MFN2^{Ile213Thr} mutant

191.0215	9.5827	3.2604	0.082728	1.7595	HMDB0000094	Citric acid	[M-H]-	9	Tricarboxylic acids and derivatives	Endogenous Food Synthetic Biological	C00158	map00020; Citrate cycle (TCA cycle); Alanine, aspartate and glutamate metabolism; Glyoxylate and dicarboxylate metabolism; Carbon fixation pathways in prokaryotes; Biosynthesis of various secondary metabolites - part 3; Biosynthesis of siderophore group nonribosomal peptides; Biosynthesis of plant secondary metabolites; Biosynthesis of phenylpropanoids; panoids; Biosynthesis of terpenoids and steroids; Biosynthesis of alkaloids derived from shikimate pathway; Biosynthesis of alkaloids derived from ornithine, lysine and nicotinic acid; Biosynthesis of alkaloids derived from histidine and purine; Biosynthesis of alkaloids derived from terpenoid and polyketide; Biosynthesis of plant hormones; Metabolic pathways; Biosynthesis of secondary metabolites; Microbial metabolism in diverse environments; Carbon metabolism; 2-Oxocarboxylic acid metabolism; Biosynthesis of amino acids; Biosynthesis of cofactors; Two-component system; Taste transduction; Glucagon signaling pathway; Central carbon metabolism in cancer
212.0413	4.2951	2.1027	0.016832	2.0793	HMDB0001511	Phosphocreatine	[M+H]+	8	Amino acids, peptides, and analogues	Endogenous	C02305	map00330; Arginine and proline metabolism; Metabolic pathways
217.1039	0.3095	-1.692	0.074128	1.7914	HMDB0029027	Prolyl-Threonine	[M+H]+	66	Amino acids, peptides, and analogues	Endogenous	-	-

Study of the MFN2^{Ile213Thr} mutant

239.1487	3.0514	1.6095	0.002226	2.2403	HMDB0139940	N-(3-aminopropyl)-3-(3,4-dihydroxyphenyl)propanimidic acid	[M+H]+	41	Benzene-diols	Endogenous	-	-
268.1042	2.1692	1.1172	0.079006	1.7731	HMDB0000050	Adenosine	[M+H]+	0	-	Endogenous Food Synthetic Biological	C00212	map00230; Purine metabolism; Metabolic pathways; ABC map01100; transporters; cGMP-PKG signaling pathway; map02010; cAMP signaling pathway; Sphingolipid signal-map04022; ing pathway; Neuroactive ligand-receptor map04024; interaction; Vascular smooth muscle contrac-map04071; tion; Regulation of lipolysis in adipocytes; Re-map04080; nin secretion; Parkinson disease; Morphine map04270; addiction; Alcoholism map04923; map04924; map05012; map05032; map05034
337.2046	0.42024	-1.2507	0.055779	1.8655	HMDB0040566	[6]-Gingerdiol 3-acetate	[M-H]-	8	Fatty alcohol esters	Food Endogenous Biological	-	-
341.3064	0.28176	-1.8275	0.070702	1.8045	HMDB0032476	Polyoxyethylene (600) monoricinoleate	[M+H]+	4	Fatty alcohols	Endogenous Food Biological	-	-
400.345	0.23881	-2.0661	0.021729	2.0443	HMDB0000222	L-Palmitoylcarnitine	[M+H]+	7	Fatty acid esters	Endogenous Food Biological	C02990	map00071; Fatty acid degradation; Fatty acid metabolism map01212
417.2988	2.3256	1.2176	0.06897	1.8113	HMDB0036886	beta-Carotinal	[M+H]+	39	Triterpenoids	Endogenous Food Biological	-	-
425.125	2.3924	1.2585	0.090263	1.7328	HMDB0003556	Chitobiose	[M-H]-	38	Carbohydrates and carbohydrate conjugates	Endogenous	C01674	map00520; Amino sugar and nucleotide sugar metabo-map01100; lism; Metabolic pathways; ABC transporters; map02010; Phosphotransferase system (PTS) map02060
455.0973	2.9588	1.565	0.041847	1.9298	HMDB0001520	Flavin mononucleotide	[M-H]-	0	-	Endogenous Food Biological	C00061	map00190; Oxidative phosphorylation; Riboflavin me-map00740; tabolism; Biosynthesis of various secondary map00997; metabolites - part 3; Biosynthesis of type II map01057; polyketide products; Metabolic pathways; map01100; Biosynthesis of secondary metabolites; map01110; Biosynthesis of cofactors; Vitamin digestion map01240; and absorption map04977

Study of the MFN2^{Ile213Thr} mutant

485.2707	0.24874	-2.0073	0.068811	1.8119	HMDB0011156	PA (0-20:4 (5Z,8Z, 11Z,14Z)/ 2:0)	[M-H]-	7	Glycero- phos- phates	Endog- enous Food Biological	-	-	-
494.3191	0.46812	-1.095	0.074051	1.7917	HMDB0010383	LysoPC (16:1 (9Z)/0:0)	[M+H]+	10	Glycero- phospho- cholines	Endog- enous Food Biological	C04230	map00564; map05231	Glycerophospholipid metabolism; Choline metabolism in cancer
504.3039	0.40545	-1.3024	0.093119	1.723	HMDB0010381	LysoPC (15:0/0:0)	[M+Na]+	4	Glycero- phospho- cholines	Endog- enous Food Biological	C04230	map00564; map05231	Glycerophospholipid metabolism; Choline metabolism in cancer
505.3484	21.317	4.4139	0.06939	1.8096	HMDB0032111	Adlupone	[M+Na]+	39	Carbonyl com- pounds	Endog- enous Food	-	-	-
512.2956	0.43086	-1.2147	0.088452	1.7392	HMDB0002639	Sulfolithocholyl- glycine	[M-H]-	53	Bile acids, alcohols and deriva- tives	Endog- enous Food Biological	C11301	-	-
539.3611	0.19266	-2.3759	0.061443	1.8416	HMDB0002815	LysoPC (18:1 (9Z)/ 0:0)	[M+NH4]+	39	Glycero- phospho- cholines	Endog- enous Food Biological	-	-	-
539.5361	2.953	1.5622	0.050784	1.8876	HMDB0041080	9-Hydroxytridec- yl docosanoate	[M+H]+	7	Fatty acid esters	Food Endog- enous Biological	-	-	-
540.329	0.48503	-1.0439	0.076519	1.7824	HMDB0010397	LysoPC (20:5 (5Z,8Z, 11Z,14Z, 17Z)/0:0)	[M-H]-	36	Glycero- phospho- cholines	Endog- enous Food Biological	C04230	map00564; map05231	Glycerophospholipid metabolism; Choline metabolism in cancer
544.3388	0.30709	-1.7033	0.009198	2.1457	HMDB0010395	LysoPC (20:4 (5Z,8Z, 11Z,14Z)/ 0:0)	[M+H]+	2	Glycero- phospho- cholines	Endog- enous Food Biological	C04230	map00564; map05231	Glycerophospholipid metabolism; Choline metabolism in cancer
553.3832	2.6147	1.3866	0.048019	1.9002	HMDB0033632	Eurohyperforin	[M+H]+	10	Monoter- penoids	Endog- enous Food Biological	-	-	-

Study of the MFN2^{Ile213Thr} mutant

565.0451	4.2373	2.0831	0.090551	1.7318	HMDB0000286	Uridine diphosphate glucose	[M-H]-	5	Pyrimidine nucleotide sugars	Endogenous Food Biological	C00029	map00040; Pentose and glucuronate interconversions; map00052; Galactose metabolism; Ascorbate and map00053; aldarate metabolism; Pyrimidine metabolism; map00240; Starch and sucrose metabolism; Amino sugar map00500; and nucleotide sugar metabolism; Neomycin, map00520; kanamycin and gentamicin biosynthesis; map00524; O-Antigen nucleotide sugar biosynthesis; map00541; Glycerolipid metabolism; Zeatin biosynthesis; map00561; Biosynthesis of ansamycins; Biosynthesis of map00908; plant secondary metabolites; Metabolic path-map01051; ways; Biosynthesis of secondary metabolites; map01060; Biosynthesis of cofactors map01100; map01110; map01240
570.3544	0.2986	-1.7437	0.007826	2.1603	HMDB0010402	LysoPC (22:5 (4Z,7Z, 10Z,13Z, 16Z)/0:0)	[M+H]+	2	Glycerophosphocholines	Endogenous Food Biological	C04230	map00564; Glycerophospholipid metabolism; Choline map05231 metabolism in cancer
590.3433	0.23028	-2.1185	0.044356	1.9175	HMDB0029334	Nummularine B	[M-H]-	76	Amino acids, peptides, and analogues	Endogenous Food Biological	-	-
594.2841	0.47768	-1.0659	0.054713	1.8701	HMDB0002581	Taurocholic acid 3-sulfate	[M-H]-	72	Bile acids, alcohols and derivatives	Endogenous Food Biological	-	-
609.5544	2.1783	1.1232	0.034531	1.9675	HMDB0060057	CE (15:0)	[M-H]-	12	Steroid esters	Food Endogenous Biological	-	-
623.5026	4.8138	2.2672	0.013259	2.108	HMDB0029958	Asitribin	[M+H]+	23	Fatty alcohols	Food Endogenous Biological	-	-
625.3451	5.122	2.3567	0.084958	1.7515	HMDB0034091	Ponasteroside A	[M-H]-	23	Steroidal glycosides	Endogenous Food Biological	-	-
645.2995	0.47979	-1.0595	0.082563	1.7601	HMDB0030736	Capsianoside IV	[M+H]+	75	Fatty acyl glycosides	Endogenous Food Biological	-	-
648.4355	2.8519	1.5119	0.023982	2.0294	HMDB0008856	PE (14:1 (9Z)/15:0)	[M+H]+	38	Glycerophosphoethanolamines	Endogenous Food Biological	-	-

Study of the MFN2^{Ile213Thr} mutant

662.1056	15.383	3.9432	0.040327	1.9373	HMDB0000902	NAD	[M-H]-	6	-	Endogenous	C00003	map00190; Oxidative phosphorylation; Thiamine map00730; metabolism; Nicotinate and nicotinamide me- map00760; tabolism; Drug metabolism - other enzymes; map00983; Metabolic pathways; Biosynthesis of cofac- map01100; tors; AMPK signaling pathway; Longevity regu- map01240; lating pathway; Longevity regulating pathway map04152; - worm; Aldosterone synthesis and secretion; map04211; Vitamin digestion and absorption map04212; map04925; map04977
675.5414	0.37932	-1.3985	0.085516	1.7495	HMDB0012097	SM (d18:1/14:0)	[M+H]+	3	Phospho-sphingo-lipids	Endogenous Food Biological	-	-
688.5332	2.9021	1.5371	0.037444	1.9521	HMDB0114836	PA (16:0/18:3 (6Z,9Z,12Z))	[M+NH4]+	61	Glycero-phosphates	Food Endogenous Biological	-	-
694.5228	0.27354	-1.8702	0.045556	1.9118	HMDB0012321	Galactosylceramide (d18:1/14:0)	[M+Na]+	0	Glyco-sphingo-lipids	Endogenous Food Biological	C02686	-
696.5389	3.1372	1.6495	0.02101	2.0491	HMDB0009213	PE (18:4 (6Z,9Z,12Z,15Z)/P-16:0)	[M+H]+	61	Glycero-phosphoethanolamines	Endogenous Food Biological	-	-
703.5717	2.5709	1.3623	0.027878	2.0053	HMDB0010169	SM (d18:1/16:0)	[M+H]+	5	Phospho-sphingo-lipids	Endogenous Food Biological	-	-
722.5062	0.38759	-1.3674	0.088715	1.7382	HMDB0009215	PE (18:4 (6Z,9Z,12Z,15Z)/P-18:1 (11Z))	[M+H]+	8	Glycero-phosphoethanolamines	Endogenous Food Biological	-	-
730.5422	0.25198	-1.9886	0.002753	2.2301	HMDB0007874	PC (14:0/18:2 (9Z,12Z))	[M+H]+	5	Glycero-phosphocholines	Endogenous Food Biological	-	-
732.5532	0.25701	-1.9601	0.014425	2.0983	HMDB0007872	PC (14:0/18:1 (11Z))	[M+H]+	1	Glycero-phosphocholines	Endogenous Food Biological	-	-

Study of the MFN2^{Ile213Thr} mutant

736.4773	0.47898	-1.0619	0.073823	1.7925	HMDB0008847	PE (14:0/22:6 (4Z,7Z,10Z,13Z,16Z,19Z))	[M+H]+	19	Glycero-phosphoethanolamines	Endogenous Food Biological	C00350	map00563; Glycosylphosphatidylinositol (GPI)-anchor biosynthesis; Glycerophospholipid metabolism; Metabolic pathways; Biosynthesis of secondary metabolites; Autophagy - other; Autophagy - yeast; Autophagy - animal; Retrograde endocannabinoid signaling; Pathogenic Escherichia coli infection; Kaposi sarcoma-associated herpesvirus infection
744.5588	0.21351	-2.2276	0.041524	1.9314	HMDB0007938	PC (15:0/18:1 (11Z))	[M-H]-	5	Glycero-phosphocholines	Endogenous Food Biological	C00157	map00564; Glycerophospholipid metabolism; Arachidonic acid metabolism; Linoleic acid metabolism; alpha-Linolenic acid metabolism; Metabolic pathways; Biosynthesis of secondary metabolites; Retrograde endocannabinoid signaling; Choline metabolism in cancer
746.5048	0.38267	-1.3858	0.009179	2.1459	HMDB0112425	PS (18:2 (9Z,12Z)/15:0)	[M+H]+	11	Glycero-phosphoserines	Food Endogenous Biological	-	-
748.5233	2.1143	1.0802	0.084229	1.7541	HMDB0005780	PE (P-16:0/22:6 (4Z,7Z,10Z,13Z,16Z,19Z))	[M+H]+	6	Glycero-phosphoethanolamines	Endogenous Food Biological	C00350	map00563; Glycosylphosphatidylinositol (GPI)-anchor biosynthesis; Glycerophospholipid metabolism; Metabolic pathways; Biosynthesis of secondary metabolites; Autophagy - other; Autophagy - yeast; Autophagy - animal; Retrograde endocannabinoid signaling; Pathogenic Escherichia coli infection; Kaposi sarcoma-associated herpesvirus infection
749.524	0.47217	-1.0826	0.037025	1.9543	HMDB0030449	20-Deoxynarasin	[M+H]+	6	Terpene glycosides	Endogenous Food Biological	-	-
769.5023	2.3254	1.2175	0.019433	2.0601	HMDB0010575	PG (16:0/18:2 (9Z,12Z))	[M+Na]+	4	Glycerophosphoglycerols	Endogenous Food Biological	-	-
772.5854	0.27789	-1.8474	0.082765	1.7594	HMDB0007946	PC (15:0/20:2 (11Z,14Z))	[M+H]+	0	Glycero-phosphocholines	Endogenous Food Biological	-	-
776.5609	2.6157	1.3872	0.034865	1.9657	HMDB0009644	PE (22:5 (4Z,7Z,10Z,13Z,16Z)/P-18:1 (11Z))	[M+H]+	3	Glycero-phosphoethanolamines	Endogenous Food Biological	-	-

Study of the MFN2^{Ile213Thr} mutant

779.53	0.16474	-2.6018	0.054714	1.8701	HMDB0115112	PA (20:1(11Z)/22:4 (7Z,10Z,13Z,16Z))	[M+H]+	37	Glycerophosphates	Food Endogenous Biological	-	-	-
780.5078	0.43494	-1.2011	0.026025	2.0166	HMDB0012313	3-O-Sulfogalactosylceramide (d18:1/16:0)	[M+H]+	27	Glycosphingolipids	Endogenous Food Biological	C06125	map00600: map01100	Sphingolipid metabolism; Metabolic pathways
780.5469	2.9935	1.5819	0.01826	2.0686	HMDB0007890	PC (14:0/22:5 (4Z,7Z,10Z,13Z,16Z))	[M+H]+	9	Glycerophosphocholines	Endogenous Food Biological	-	-	-
794.5675	0.40669	-1.298	0.015275	2.0914	HMDB0007956	PC (15:0/22:5 (4Z,7Z,10Z,13Z,16Z))	[M+H]+	3	Glycerophosphocholines	Endogenous Food Biological	-	-	-
797.525	0.27068	-1.8854	0.033184	1.9749	HMDB0010581	PG (16:0/22:4 (7Z,10Z,13Z,16Z))	[M-H]-	11	Glycerophosphoglycerols	Endogenous Food Biological	-	-	-
804.548	0.41074	-1.2837	0.010467	2.1332	HMDB0007889	PC (14:0/22:4 (7Z,10Z,13Z,16Z))	[M+Na]+	4	Glycerophosphocholines	Endogenous Food Biological	-	-	-
806.5619	0.27614	-1.8565	0.032865	1.9766	HMDB0004866	LacCer (d18:1/12:0)	[M+H]+	1	-	Endogenous Food Biological	-	-	-
825.5572	0.22222	-2.1699	0.033226	1.9746	HMDB0061422	PC (DiMe (9,3)/MonoMe (11,3))	[M+H]+	7	Glycerophosphocholines	Endogenous Food Biological	-	-	-
826.5584	8.1981	3.0353	0.001533	2.2558	HMDB0008189	PC (18:3(6Z,9Z,12Z)/22:6 (4Z,7Z,10Z,13Z,16Z,19Z))	[M-H]-	23	Glycerophosphocholines	Endogenous Food Biological	-	-	-
840.5239	0.29165	-1.7777	0.057932	1.8563	HMDB0061555	PS (DiMe (11,3)/DiMe (9,3))	[M+H]+	26	Glycerophosphoserines	Endogenous Food Biological	-	-	-
854.6698	0.33573	-1.5746	0.068492	1.8131	HMDB0009278	PE (20:1 (11Z)/24:1 (15Z))	[M-H]-	6	Glycerophosphoethanolamines	Endogenous Food Biological	-	-	-

Study of the MFN2^{Ile213Thr} mutant

865.5056	5.0623	2.3398	0.08721	1.7435	HMDB0116605	PG (22:6 (4Z,7Z, 10Z,13Z, 16Z,19Z)/ 22:6 (4Z,7Z, 10Z,13Z, 16Z,19Z))	[M-H]-	4	Glycero- phospho- glycerols	Food Endog- enous Biological	-	-
889.5481	0.46291	-1.1112	0.05578	1.8655	HMDB0009785	PI (16:0/ 20:0)	[M+Na]+	33	Glycero- phospho- inositols	Endog- enous Food Biological	-	-
913.5269	0.40101	-1.3183	0.078158	1.7763	HMDB0034650	Soyasaponin II	[M+H]+	12	Terpene glyco- sides	Endog- enous Food Biological	C12081	-
952.5933	0.2021	-2.3068	0.037455	1.952	HMDB0061563	PS (DiMe (11,5)/ DiMe (13,5))	[M+H]+	36	Glycero- phospho- serines	Endog- enous Food Biological	-	-
1151.703	0.1284	-2.9613	0.069028	1.811	HMDB0004844	Ganglioside GM3 (d18:1/ 16:0)	[M-H]-	2	Glyco- sphingo- lipids	Endog- enous Food Biological	C04730	-